BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
FDA advisory committee meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis scheduled for September 27, 2023 BrainStorms Biologics License Application for NurOwn has a Prescription... -Today at 07:06 am- MarketScreener
Source: marketscreener.com